AbbVie Inc.
ABBV
$144.18
$0.76820.54%
| Weiss Ratings | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B- | |||
| Rating Factors | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Weak | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.36 | |||
| Price History | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 4.11% | |||
| 30-Day Total Return | -1.41% | |||
| 60-Day Total Return | -2.29% | |||
| 90-Day Total Return | -2.18% | |||
| Year to Date Total Return | -7.63% | |||
| 1-Year Total Return | -8.36% | |||
| 2-Year Total Return | 33.34% | |||
| 3-Year Total Return | 55.54% | |||
| 5-Year Total Return | 94.42% | |||
| 52-Week High % Change | -14.69% | |||
| 52-Week Low % Change | 9.51% | |||
| Price | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $168.11 | |||
| 52-Week Low Price | $130.96 | |||
| 52-Week Low Price (Date) | Jun 28, 2023 | |||
| 52-Week High Price (Date) | Jan 06, 2023 | |||
| Valuation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $253.20B | |||
| Enterprise Value | 301.12B | |||
| Price/Earnings (TTM) | 39.26 | |||
| Earnings Per Share (TTM) | 3.65 | |||
| Earnings Per Share Growth | -51.30% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.61 | |||
| Price/Book (Q) | 20.94 | |||
| Enterprise Value/Revenue (TTM) | 5.46 | |||
| Price | $144.17 | |||
| Enterprise Value/EBITDA (TTM) | 11.61 | |||
| Enterprise Value/EBIT | 17.55 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.771B | |||
| Dividend Yield | 4.13% | |||
| Div. Per Share (Most Recent) | $1.48 | |||
| Dividend Per Share (TTM) | $5.92 | |||
| Payout Ratio (TTM) | 159.95% | |||
| Dividend Per Share (Most Recent) | $1.48 | |||
| Company Info | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 847 932 7900 | |||
| Address | 1 North Waukegan Road North Chicago, IL 60064-6400 | |||
| Website | www.abbvie.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 31.12% | |||
| Profit Margin | 11.81% | |||
| Management Effectiveness | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 7.73% | |||
| Return on Equity | 46.32% | |||
| Income Statement | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $55.14B | |||
| Total Revenue (TTM) | $55.14B | |||
| Revenue Per Share | $31.13 | |||
| Gross Profit (TTM) | $37.13B | |||
| EBITDA (TTM) | $25.94B | |||
| EBIT (TTM) | $17.16B | |||
| Net Income (TTM) | $6.51B | |||
| Net Income Avl. to Common (TTM) | $6.51B | |||
| Total Revenue Growth (Q YOY) | -5.97% | |||
| Earnings Growth (Q YOY) | -54.93% | |||
| EPS Diluted (TTM) | $3.65 | |||
| EPS Diluted Growth (Q YOY) | -54.75% | |||
| Balance Sheet | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $13.29B | |||
| Cash Per Share (Q) | $7.50 | |||
| Total Current Assets (Q) | $33.22B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $12.13B | |||
| Current Ratio (Q) | 0.955 | |||
| Book Value Per Share (Q) | $6.85 | |||
| Total Assets (Q) | $136.22B | |||
| Total Current Liabilities (Q) | $34.77B | |||
| Total Debt (Q) | $61.18B | |||
| Total Liabilities (Q) | $124.09B | |||
| Total Common Equity (Q) | $12.09B | |||
| Cash Flow | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -$1.66B | |||
| Cash from Financing (TTM) | -$22.41B | |||
| Net Change in Cash (TTM) | $1.46B | |||
| Levered Free Cash Flow (TTM) | $22.78B | |||
| Cash from Operations (TTM) | $25.51B | |||
